Skip to content
ATLAS PREP HQ
Longevity

NAD+

Oxidized nicotinamide adenine dinucleotide (metabolic coenzyme; not a peptide)

Cellular coenzyme research centered on energy metabolism, redox reactions, and DNA-repair pathways.

Limited Human Evidence

Route

Subcutaneous in the community reference

Common format

500 mg vial

Research focus

cellular energy

Evidence level

Limited Human Evidence

Typical cycle

8–16 weeks

Longevity research motifLongevity

NAD+ in 30 seconds

Atlas Fast Read

What it is

Oxidized nicotinamide adenine dinucleotide (metabolic coenzyme; not a peptide)

Why people care

Cellular coenzyme research centered on energy metabolism, redox reactions, and DNA-repair pathways.

Human evidence

Limited Human Evidence — Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

Biggest misconception

A major gap is whether injected NAD+ reliably enters target tissues/cells or simply changes extracellular metabolism. Optimal route, exposure, durability, clinical outcomes, and comparison with NAD precursors remain unresolved.

Bottom line

NAD biology is fundamental; that does not mean an NAD+ injection automatically 'recharges' every tissue.

Overview

What is NAD+?

NAD+ is an essential cellular redox coenzyme, not a peptide. It appears in peptide and longevity clinics because it sits at the center of mitochondrial energy metabolism, DNA-repair enzymes, and sirtuin biology.

NAD was discovered in the early 20th century during fermentation research and later recognized as a universal redox coenzyme. Modern longevity interest centers on age-related NAD decline, sirtuins, PARPs, and mitochondrial metabolism.

Mechanism

How it works

Functions as an electron carrier in redox metabolism and as a consumed substrate for sirtuins, PARPs, and other enzymes. Raising extracellular NAD does not guarantee predictable intracellular tissue increases, which is a major translational uncertainty.

Research areas

cellular energyDNA repairsirtuinsmitochondrial metabolism

Evidence

What does the evidence actually say?

Limited Human Evidence

Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

NAD biology is established in humans, but evidence that IV or subcutaneous NAD+ itself produces durable longevity, cognitive, or performance benefits is limited. Human trials more often study NAD precursors such as nicotinamide riboside or NMN, which cannot be treated as direct proof for NAD+ injections.

Preclinical evidence

Preclinical biology strongly supports NAD as essential to mitochondrial redox reactions and as a substrate for sirtuins/PARPs. Animal studies of NAD restoration and precursor supplementation support mechanistic interest, but direct injectable-NAD translation remains uncertain.

Knowledge gaps

A major gap is whether injected NAD+ reliably enters target tissues/cells or simply changes extracellular metabolism. Optimal route, exposure, durability, clinical outcomes, and comparison with NAD precursors remain unresolved.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

community sources SC reference: 50–100 mg/day. IV wellness protocols often use much larger amounts, but evidence and tolerability are route-dependent and protocols are not interchangeable.

Frequency

Once daily in the community SC titration.

Timing

Earlier in the day is often preferred if stimulation/insomnia occurs, but this is not evidence-based.

Route

Subcutaneous in the community reference; IV and oral precursor strategies are more commonly studied/used in humans.

Cycle length

8–16 weeks

Reconstitution

Community reference: 3 mL per 500 mg vial = about 166.7 mg/mL.

Storage

Community reference: lyophilized frozen; reconstituted 2–8 °C for up to 14 days and protected from light.

Monitoring

CMP/CBC and adverse effects are reasonable general measures. Direct blood NAD testing is available in some settings but is not a validated treatment target for longevity.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Rapid IV NAD+ can cause nausea, chest/abdominal discomfort, flushing, headache, cramping or a sense of pressure; slower administration is often better tolerated. Subcutaneous use can cause local pain/irritation. Long-term safety of high-dose wellness use is not well defined.

Contraindications

No standardized longevity-treatment contraindication profile exists. Significant liver/kidney disease, pregnancy/breastfeeding, active cancer treatment and severe acute illness warrant clinician review.

Interactions

Robust interaction studies are lacking. Cancer therapies and drugs that intentionally alter NAD metabolism are a special concern; do not assume NAD supplementation is neutral during oncology treatment.

Stacks

Common stacks

NAD+ + MOTS-c

Often discussed as a mitochondrial/metabolic research stack.

No controlled clinical evidence for combined longevity benefit.

NAD+ + SS-31

Pairs cellular redox cofactor support with mitochondrial-membrane targeting.

No controlled evidence for combined wellness/longevity outcomes.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

NAD biology is fundamental; that does not mean an NAD+ injection automatically 'recharges' every tissue. Atlas separates strong basic science from the much thinner evidence for IV/SC longevity outcomes and from evidence on NAD precursors.

More in Longevity

Longevity

Cortagen

Peptide bioregulator research focused on neuroregeneration, brain aging, and cognitive function.

Read guide

Longevity

Epitalon

Pineal-derived tetrapeptide research exploring telomerase activity, circadian biology, and healthy aging.

Read guide

Longevity

FOXO4-DRI

Experimental senolytic peptide research investigating selective removal of senescent cells.

Read guide